



NDA 15-923/S-086  
NDA 18-701/S-063

**SUPPLEMENT APPROVAL**

Ortho-McNeil-Janssen Pharmaceuticals, Inc.  
Attention: Mary Mulligan  
Regulatory Manager, Global Regulatory Affairs  
1000 U.S. Highway 202, P.O. Box 300  
Raritan, NJ 08869-0602

Dear Ms. Mulligan:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received February 22, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Haldol (haloperidol) IM Injection and Haldol (haloperidol) Decanoate IM Injection.

These “Changes Being Effectuated” supplemental new drug applications incorporate “Instructions for Opening Ampule” under the Dosage and Administration section of labeling.

We have completed our review of these supplemental applications and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling

[21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email CAPT Steven D. Hardeman, R.Ph., Chief, Project Management Staff, at [Steven.Hardeman@FDA.HHS.GOV](mailto:Steven.Hardeman@FDA.HHS.GOV).

Sincerely,

*{See appended electronic signature page}*

Thomas Laughren, M.D.  
Director  
Division of Psychiatry Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

THOMAS P LAUGHREN  
03/01/2011